|Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium|
AF Olumi, GD Grossfeld, SW Hayward, PR Carroll, GR Cunha, P Hein, ...
Breast Cancer Research 2 (1), 1-1, 2000
|5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes|
WM Rideout, GA Coetzee, AF Olumi, PA Jones
Science 249 (4974), 1288-1290, 1990
|Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder|
AF Olumi, YC Tsai, PW Nichols, DG Skinner, DR Cain, LI Bender, ...
Cancer research 50 (21), 7081-7083, 1990
|MR imaging of renal masses: correlation with findings at surgery and pathologic analysis|
I Pedrosa, MR Sun, M Spencer, EM Genega, AF Olumi, WC Dewolf, ...
Radiographics 28 (4), 985-1003, 2008
|In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation|
PA Gameiro, J Yang, AM Metelo, R Pérez-Carro, R Baker, Z Wang, ...
Cell metabolism 17 (3), 372-385, 2013
|Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy|
IF San Francisco, WC DeWOLF, S Rosen, M Upton, AF Olumi
The Journal of urology 169 (1), 136-140, 2003
|Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage|
CH Spruck, WM Rideout, AF Olumi, PF Ohneseit, AS Yang, YC Tsai, ...
Cancer research 53 (5), 1162-1166, 1993
|Role of chromosome 9 in human bladder cancer|
N Miyao, YC Tsai, SP Lerner, AF Olumi, CH Spruck, M Gonzalez-Zulueta, ...
Cancer research 53 (17), 4066-4070, 1993
|Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism|
SM Fendt, EL Bell, MA Keibler, SM Davidson, GJ Wirth, B Fiske, ...
Cancer research 73 (14), 4429-4438, 2013
|pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-κB agonist Card9 by CK2|
H Yang, YA Minamishima, Q Yan, S Schlisio, BL Ebert, X Zhang, L Zhang, ...
Molecular cell 28 (1), 15-27, 2007
|Persistent c-FLIP (L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand–mediated apoptosis in prostate cancer|
X Zhang, TG Jin, H Yang, WC DeWolf, R Khosravi-Far, AF Olumi
Cancer research 64 (19), 7086-7091, 2004
|Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer|
AA Aizer, JJ Paly, AL Zietman, PL Nguyen, CJ Beard, SK Rao, ID Kaplan, ...
Journal of Clinical Oncology 30 (25), 3071-3076, 2012
|Metformin use and prostate cancer risk|
MA Preston, AH Riis, V Ehrenstein, RH Breau, JL Batista, AF Olumi, ...
European urology 66 (6), 1012-1020, 2014
|Personalized medicine for the management of benign prostatic hyperplasia|
SK Bechis, AG Otsetov, R Ge, AF Olumi
The Journal of urology 192 (1), 16-23, 2014
|Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations|
L Li, L Zhang, X Zhang, Q Yan, YA Minamishima, AF Olumi, M Mao, ...
Molecular and cellular biology 27 (15), 5381-5392, 2007
|MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP (L)|
W Li, X Zhang, AF Olumi
Cancer research 67 (5), 2247-2255, 2007
|The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection|
JO Ung, IF San Francisco, MM Regan, WC DeWOLF, AF Olumi
The Journal of urology 169 (1), 130-135, 2003
|Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system|
F Dong, C Wang, AB Farris, S Wu, H Lee, AF Olumi, WS McDougal, ...
The American journal of surgical pathology 36 (6), 838-843, 2012
|c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells|
X Zhang, L Zhang, H Yang, X Huang, H Otu, TA Libermann, WC DeWolf, ...
Cancer research 67 (19), 9425-9434, 2007
|Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity|
GD GROSSFELD, AF OLUMI, JA CONNOLLY, K CHEW, J GIBNEY, ...
The Journal of urology 159 (5), 1437-1443, 1998